Back to Search Start Over

Berberine: An inspiring resource for the treatment of colorectal diseases.

Authors :
Cao, Fang
Xia, Weiyang
Dai, Shengcheng
Wang, Changkang
Shi, Rui
Yang, Yujie
Guo, Cui
Xu, Xue liang
Luo, Jian
Source :
Biomedicine & Pharmacotherapy. Nov2023, Vol. 167, pN.PAG-N.PAG. 1p.
Publication Year :
2023

Abstract

Colorectal cancer is a prevalent malignant tumor with a complex and diverse pathogenesis. In recent years, natural products have shown promising application prospects as sources of anticancer drugs. BBR, a class of benzoquinoline alkaloids extracted from various plants, is widely used in disease treatments owing to its pharmacological activities, including antibacterial, anti-inflammatory, antioxidant, anticancer, and anti-angiogenesis properties. Research has demonstrated that BBR exerts an anti- Salmonella and - Escherichia coli infection effect, attenuating inflammatory reactions by inhibiting harmful bacteria. During the stage of colorectal precancerous lesions, BBR inhibits the activity of cell cyclin by regulating the PI3K/AKT, MAPK, and Wnt signaling pathways, thereby decelerating the cell cycle progression of polyp or adenoma cells. Moreover, the inhibitory effect of BBR on colorectal cancer primarily occurs through the regulation of the cancer cell cycle, anti-angiogenesis, gut microbiota, and antioxidant pathways. The specific involved pathways include the MPK/ERK, NF-kB, and EGFR signaling pathways, encompassing the regulation of Bcl-2 family proteins, vascular endothelial growth factor, and superoxide dismutase. This study reviews and summarizes, for the first time, the specific mechanisms of action of BBR in the carcinogenesis process of colorectal cancer, providing novel insights for its clinical application in intestinal diseases. [Display omitted] • The beneficial effects of berberine on the multi-step and phenotypic regulation of CRC occurrence and development. • The pharmacological mechanism of berberine in different studies involving various intestinal diseases. • BBR antagonizes colorectal cancer through five pathways. • BBR has shown the potential for effective treatment of colorectal diseases through multiple channels and targets. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
07533322
Volume :
167
Database :
Academic Search Index
Journal :
Biomedicine & Pharmacotherapy
Publication Type :
Academic Journal
Accession number :
172976555
Full Text :
https://doi.org/10.1016/j.biopha.2023.115571